Transitioning Between Treprostinil Formulations: Evidence and Strategies
Megan Clarke, Ali Ataya, Alison M. Turkin, Raj Parikh, Kyle Davis, Chad E. Miller, Alexander Kantorovich, Thomas Winkler, Steven J. Cassady

TL;DR
This review summarizes evidence on transitioning between different forms of treprostinil, a drug used to treat pulmonary hypertension, highlighting the need for personalized strategies.
Contribution
The paper consolidates existing evidence to guide clinicians on transitioning between treprostinil formulations with a focus on individualized approaches.
Findings
Over 100 patients were studied, with crossover strategies being the most common transition method.
Approximately 80% of transitions were successful, though success criteria varied across studies.
Unsuccessful transitions were often due to disease progression or therapy intolerance.
Abstract
Treprostinil is a prostacyclin analog available in four formulations: parenteral, oral, inhalation solution, and inhalation powder. All formulations of treprostinil are indicated for the treatment of pulmonary arterial hypertension; the inhaled formulations are also approved for pulmonary hypertension associated with interstitial lung disease. Transitions between formulations are frequent in clinical practice but lack standardized guidance. This review summarizes published evidence regarding safety, efficacy, and techniques of transitioning between treprostinil formulations. The evidence includes over 100 patients across various settings, with crossover transition strategies most frequently employed. Approximately 80% of cases reviewed were deemed successful; however, it should be noted there was no standardized definition for success across publications. Unsuccessful transitions were…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPulmonary Hypertension Research and Treatments · Phosphodiesterase function and regulation · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
